Business
Royal Navy destroyer HMS Dragon sets sail for eastern Mediterranean
Royal Navy warship HMS Dragon is heading to the eastern Mediterranean, a week after its deployment was announced.
The Type 45 destroyer is capable of shooting down drones and ballistic missiles fired by Iran and its proxies as the Middle East crisis continues.
The crew of the vessel were seen lining the deck as the ship moved out of Portsmouth Harbour.
Officials insisted the ship had been prepared as quickly as possible for deployment, with six weeks’ worth of work squeezed into six days.
The announcement of the deployment of the ship came in response to a drone attack which hit the RAF Akrotiri base in Cyprus.
HMS Dragon, which has a crew of around 200, is capable of firing eight Sea Viper missiles in under 10 seconds to take down aerial targets.
Its commanding officer, Commander Iain Giffin, said: “We are trained for this, we are ready for this, we have the equipment and people, we have the support of the British people and, most importantly, our families and friends.”
Defence Secretary John Healey praised the naval personnel and civilian teams who “worked flat out” to prepare HMS Dragon for deployment, adding: “What is normally six weeks of work was completed in just six days – a remarkable effort delivered around the clock. They are the very best of Britain in action.”
But Tory leader Kemi Badenoch said: “After two weeks of Keir Starmer’s dithering, HMS Dragon is finally leaving port.
“I wish our brave servicemen and women a safe deployment.”
The departure of HMS Dragon came after the Ministry of Defence confirmed a second British ship was being prepared for a potential deployment.
Landing ship RFA Lyme Bay has aviation and medical facilities, allowing it to assist if the crisis continues to deepen and an evacuation is needed from Lebanon, where Israel has been targeting Iran’s Hezbollah allies.
A Ministry of Defence spokesman said: “As part of prudent planning, we have taken the decision to bring RFA Lyme Bay to heightened readiness as a precaution, should she be needed to assist in maritime tasks in the eastern Mediterranean.”
Markets calmed after US President Donald Trump suggested the military action would be a “short-term excursion” rather than a more prolonged war and threatened “death, fire and fury” against Iran unless vessels were allowed through the Strait of Hormuz, a vital maritime oil and gas route.
But nervousness around the potential impact of higher energy costs still lingered.
The UK’s budget watchdog warned inflation this year could be higher than it had previously estimated.
Professor David Miles, a member of the Office for Budget Responsibility (OBR’s) budget responsibility committee, told MPs: “Right now, if prices don’t change from where they are – both the spot prices and market expectations for futures prices, which is particularly important for the Ofgem price cap – we think the inflation rate would end the year not near 2%, but nearer 3%.”
In London the FTSE 100 index closed 1.59%, or 162.72 points, higher at 10,412.24 at the end of trading on Tuesday, as the major European markets all regained ground.
It was partly driven by a sharp drop in the price of oil, with Brent crude falling by 12.7% to 86.38 US dollars a barrel.
On Wall Street, the Dow Jones and S&P are also higher after recovering from an initial dip after the markets opened.
US Air Force B1 bombers were seen taking off from RAF Fairford in Gloucestershire as the Trump administration indicated an escalation in its raids on Iran.
US defence secretary Pete Hegseth said Tuesday would be “our most intense day of strikes inside Iran” so far in the campaign.
He said that the last 24 hours had seen Iran fire the lowest amount of missiles it had launched since the crisis began.
Business
‘I had £20,000 stolen and had to fight a 13-month fraud reporting rule to get it back’
Sarah has now got her money back but there are calls to reform the deadline for reporting scams to banks.
Source link
Business
Why Spotify has no button to filter out AI music
Music streamer Deezer allows users to filter out AI music, so why does Spotify not offer the same?
Source link
Business
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA.
Spencer Grant | Universal Images Group | Getty Images
Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval from the U.S. Food and Drug Administration.
The company’s treatment uses Nobel Prize-winning technology Crispr to edit DNA and turn off the gene that controls production of a peptide that’s overactive in people with hereditary angioedema, causing them to experience potentially life-threatening swelling attacks. Intellia’s treatment is administered once through an hourslong infusion, making the edits directly in the liver.
Intellia said the one-time treatment reduced attacks by 87% compared with a placebo, meeting the study’s main goal. Six months after treatment, 62% of patients were free from attacks and weren’t using other therapies, Intellia said.
The company described the safety and tolerability of the treatment as “favorable,” reporting the most common side effects were infusion-related reactions, headaches and fatigue. Analysts were closely watching safety in the trial since a patient in a separate trial of a different treatment from Intellia died. That patient developed a liver injury and ultimately died from septic shock following an ulcer, according to the company.
“When you think about where we started with Crispr, just 12 years ago with some of the fundamental insights, I think there was a lot of talk about what might be possible, and we’ve had reports along the way in terms of milestones, but this is the first Phase 3 data in any indication with in vivo Crispr where you’re actually changing a gene that causes disease,” said Intellia CEO John Leonard.
The only FDA-approved Crispr-based medicine comes from Vertex Pharmaceuticals. Called Casgevy, the gene editing is done outside the body, or ex vivo. The process requires collecting a person’s blood cells, making the edits outside the body, then reinfusing them back into a patient. Intellia’s treatment, meanwhile, makes the edits inside the body, or in vivo.
Intellia said it has started a rolling application with the FDA and plans to complete the filing in the second half of this year. The company expects to launch the treatment in the U.S. in the first half of next year, if it’s approved.
If approved, Intellia’s treatment, lonvoguran ziclumeran, will compete with about a dozen other chronic drugs for HAE. Despite the allure of a one-time treatment, genetic medicines haven’t always been a commercial successes. BioMarin withdrew its gene therapy for Hemophilia A because of weak sales, for example.
Leonard said there are important differences between the two, like the fact that BioMarin’s therapy faced questions about how long the effects would last. In contrast, he said Intellia hasn’t seen a single case in almost six years where the effects diminished over time.
Despite the results, he’s reluctant to call Intellia’s treatment a functional cure.
“I think this is a tipping point for the disease and tipping point for Crispr-based in vivo therapy where you can make a change [and] it’s permanent,” Leonard said. “And, as far as we can tell, we don’t have a single patient in this program or other program where there’s been any waning of the effect of what we did to the gene or the effect of what we’ve seen with the clinical aspects of the disease itself. So it’s pretty exciting.”
Clarification: This story has been updated to clarify that a patient in a separate trial of a different treatment from Intellia developed acute liver injury and ultimately died from septic shock following an ulcer.
-
Sports1 week agoNCAA men’s gymnastics championship: All-time winners list
-
Sports1 week agoWWE WrestleMania 42 Night 2: Live match results and analysis
-
Fashion1 week agoUK’s Sosandar returns to profitability amid robust FY26 performance
-
Politics7 days agoUK’s Starmer seeks to deflect blame over Mandelson appointment
-
Entertainment1 week agoLee Anderson, Zarah Sultana kicked out of UK Parliament for calling PM ‘liar’
-
Business1 week agoHow Trump’s psychedelics executive order could unlock stalled cannabis reform
-
Business1 week agoNo fuel shortage: Govt assures 100% domestic LPG, PNG, CNG supply amid Hormuz energy crunch – The Times of India
-
Sports1 week agoQuetta Gladiators opt to bowl after winning toss against Peshawar Zalmi in PSL 11 clash
